PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

• Status: Recruiting
• Trial end date: 2024-08-30
• Target enrollment: 0
• Participant gender: Male

Summary

This is a phase I study which will test the safety of different doses of the patients own immune cells which have been changed to help recognize and destroy the cancer cells. The investigators want to find out what effects, good and/or bad, it has on the body and on the prostate cancer. The immune cells (T cells) used in this study will be the patients own immune cells. They will be removed from the patients blood, changed in the laboratory, and then put back into their body. T cells help the body fight infections. These cells may also kill cancer cells in some cases. Right now the patients T cells are unable to kill the cancer cells. For this reason, the physician will change the T cells by putting in a gene so that they may be able to better recognize and kill the prostate cancer cells. A gene is a portion of information which comes from the DNA and tells the cell what to do. This gene will be put into the patients T cells by a weakened virus. It is hoped that this approach will help the T cells recognize the prostate cancer tumor cells and possibly kill them. This is an entirely new treatment for prostate cancer and it is not known if it will have any beneficial or unexpected harmful effects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
• Collaborator: The First Affiliated Hospital of Soochow University
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• Evidence of metastatic disease in bone on bone scan, CT scan, and/or by MRI atany time following the initial diagnosis of prostate cancer;

• The corresponding antigens such as PSMA and PSCA/PDL1 were highly expressed;

• Male patients aged between 18 and 65;

• Karnofsky score ≥ 60, ECOG≤ 2;

• Important organ function as defined by the following: cardiac ejection fraction ≥ 50%; electrocardiogram showed no obvious abnormalities; creatinine clearance rate calculated by using Cockcroft- Gault formula ≥40ml/min ; ALT/AST≤ 3×the institution normal upper limit; total bilirubin ≤2.0mg/dl; coagulation function: PT/ APPT<2 ×the institution normal upper limit; SpO2 >92%; Blood: hemoglobin>80g/L, ANC ≥ 1, PLT ≥ 50×109/L;

• There is measurable target lesion;

• Voluntary informed consent is given;

Exclusion Criteria:

• Immunosuppressive drugs or hormones were used a week before admission;

• Severe active infection;

• Human immunodeficiency virus (HIV) positive;

• Active hepatitis B or C infection;

• Past medical history of other malignancies. Not included: patients who have been cured at any time prior to the treatment of the skin basal or squamous cell carcinoma and cervical carcinoma in situ; the other tumor has not listed above, but has been used and only cured by surgery, without further treatment by other measures, the subjects of disease-free survival more than 5 years, can be included in the study;

• Patients participating in other clinical trials;

• The researchers thought the subjects were unfit for inclusion or unable to participate in or complete the study;

• Patients with congenital immunodeficiency;

• There is a history of myocardial infarction and serious arrhythmia within six months;